During the past decade, Tri-County Hematology & Oncology Associates, Inc. conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 3 clinical trials were completed, i.e. on average, 23.1% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tri-County Hematology & Oncology Associates, Inc." #1 sponsor was "Celgene" with 3 trials, followed by "Accelerated Community Oncology Research Network" with 1 trials sponsored, "Biodesix, Inc." with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Denovo Biopharma LLC" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tri-County Hematology & Oncology Associates, Inc." #1 collaborator was "Amalgam Rx" with 1 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "Iqvia Pty Ltd" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Tri-County Hematology & Oncology Associates, Inc." are "Lung Cancer" (3 trials), "Breast Cancer" (2 trials), "Ovarian Cancer" (2 trials), "Advanced Unresectable or Metastatic Solid Malignancy" (1 trials) and "Bladder Cancer" (1 trials). Many other conditions were trialed in "Tri-County Hematology & Oncology Associates, Inc." in a lesser frequency.

Most popular intervention types in "Tri-County Hematology & Oncology Associates, Inc." are "Drug" (11 trials), "Other" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "5-Fluorouracil" (1 trials), "Abraxane (Induction)" (1 trials), "Abraxane (Maintenance)" (1 trials) and "Alectinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tri-County Hematology & Oncology Associates, Inc." are 15 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Tri-County Hematology & Oncology Associates, Inc.". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Tri-County Hematology & Oncology Associates, Inc., undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Tri-County Hematology & Oncology Associates, Inc., 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".